



Leading Cell Line Development

NeuClone has developed technology for the safe and cost-effective manufacturing of biological drugs. The Company licenses regulatory-approved cell lines that are expertly engineered to produce a range of protein therapeutics. NeuClone's platform technology is used to generate industrial cell lines and manufacturing processes to produce biological drug APIs. At the core of NeuClone is a willingness for our client's to succeed, and the company provides ongoing support and intensive in-house training. With facilities in Sydney, Australia, the company is providing its clients with the tools, skills and capabilities to manufacture biological drugs using its proprietary cell lines and processes.

Fast track biosimilar API production

Many generic pharmaceutical companies have made the strategic decision to include biotech drugs in their existing pharmaceutical product offerings. The patent expiry of many leading biotech drugs has created a number of highly attractive market opportunities for generic versions collectively named 'biosimilars'. NeuClone's highly experienced team has worked on the development of several originator drugs and brings expertise to the biosimilar stage, enabling our clients to exploit this nascent market. NeuClone has a growing portfolio of API-producing cell lines with many available for immediate licensing.

NeuClone's Technology

(I) A highly effective protein production platform

NeuClone has developed a highly effective expression system that maximizes the levels of recombinant protein biosynthesis and secretion in CHO cells. Expression of recombinant protein is achieved using the company's proprietary expression vectors and metabolically enhanced CHO cells, together named NeuCHO™.

(II) Intellectual Property

NeuClone is continuing to develop a broad range of intellectual property (IP). Much of NeuClone's value lies in its depth of expertise in the area of cell line engineering and working with mammalian cells for commercial scale production. The company has IP in the following areas:

1. DNA expression vectors (*pNeu* and *pNeuMAB*);
2. The characterized parental CHO cell line, engineered for enhanced viability and productivity;
3. Process for rapid isolation of stable, high-yield cell lines;
4. SOP and documentation systems for cell line development providing traceable history of cell lines;
5. NeuCHO™ cell lines producing biosimilar APIs.



NeuClone's advantage in a cost-sensitive industry:

Many global generic pharmaceutical companies are developing biosimilars. Prominent obstacles to entry into this market include the sizeable investments in time and expertise associated with cell line engineering and process development. NeuClone has a number of distinct advantages to offer drug manufacturers who are looking to invest in biologics, including:

Reduced risk of investment

Clients rely on NeuClone's knowledge, skills and expertise to provide high quality cell lines for use in manufacturing their biological drugs of choice.

Reduced regulatory risk

NeuClone's cell lines are generated according to European Medicines Agency (EMA) guidelines. Pursuant to this, workflows are in serum and animal-protein-free culture media. Cell line history is documented and traceable.

Reduced time to market

By licensing NeuClone's cell lines, clients can begin manufacturing immediately and reduce their time to market.

Reduced cost

By using NeuClone's cell lines, our clients avoid making erroneous experimental decisions and costly mistakes in creating and optimizing highly complex CHO cell lines for API production.

Experience, Knowledge and Training

NeuClone has a dedicated team of experienced scientists with extensive expertise in cell line development. We offer comprehensive training to ensure our clients' scientific teams are skilled in cell line and process development. With hands-on training in our facilities these scientists are well equipped to develop their own products using NeuClone's suite of technologies.

Partnering Opportunities

NeuClone is well placed to enter into partnerships with drug manufacturers who have experience in commercial scale manufacturing, industry standard quality control systems and those with a strong track record in regulatory compliance.

For more information on licensing and partnering opportunities please contact:

NeuClone Pty Ltd
Australian Technology Park
National Innovation Centre
4 Cornwallis St. Eveleigh NSW 2015
AUSTRALIA

Noelle Sunstrom, PhD, MBA, FAICD
Chief Executive Officer
n.sunstrom@neuclone.com
www.neuclone.com
+612 9209 4020